We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Mgc Pharmaceuticals Limited | LSE:MXC | London | Ordinary Share | AU000000MXC6 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.00 | 4.76% | 22.00 | 21.00 | 23.00 | 23.00 | 21.00 | 21.00 | 20,732 | 11:40:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drug & Proprietary Stores | 4.16M | -20.82M | -0.4749 | -0.86 | 17.98M |
TIDMMXC
RNS Number : 6092R
MGC Pharmaceuticals Limited
09 March 2021
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity MGC Pharmaceuticals Limited ABN 30 116 800 269
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director Stephen Barry Parker Date of last notice 13 March 2019 ----------------------------------
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect Indirect interest Nature of indirect Held through a UK Individual Savings interest Account ("ISA") (including registered holder) Registered Holder is Barclays Bank PLC Note: Provide details of the circumstances giving rise to the relevant interest. ---------------------------------------- Date of change 5 March 2021 ---------------------------------------- No. of securities held Nil prior to change ---------------------------------------- Class Ordinary shares ---------------------------------------- Number acquired 282,316 ---------------------------------------- Number disposed - ---------------------------------------- Value/Consideration GBP 9,999.99 Note: If consideration is non-cash, provide details and estimated valuation ---------------------------------------- No. of securities held 282,316 ordinary shares after change ---------------------------------------- Nature of change On-market trade Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back ----------------------------------------
Part 2 - Change of director's interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract N/A Nature of interest ---- Name of registered holder (if issued securities) ---- Date of change ---- No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed ---- Interest acquired ---- Interest disposed ---- Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation ---- Interest after change ----
Part 3 - + Closed period
Were the interests in the securities No or contracts detailed above traded during a + closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? --- If prior written clearance was provided, on what date was this provided? ---
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity MGC Pharmaceuticals Limited ABN 30 116 800 269
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director Brett Anthony Mitchell Date of last notice 12 August 2020 ------------------------------------
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect Indirect interest Nature of indirect Brett and Michelle Mitchell <Mitchell interest Spring Family A/C> (including registered Trustee holder) Brett and Michelle Mitchell <Lefthanders Note: Provide details Super Fund A/C> of the circumstances Trustee giving rise to the relevant interest. ------------------------------------------------------- Date of change 5 March 2021 ------------------------------------------------------- No. of securities held Brett and Michelle Mitchell <Mitchell prior to change Spring Family A/C> 22,264,444 Fully Paid Ordinary Shares 3,750,000 Performance Rights 277,777 Listed Options exercisable at $0.045 each expiring 31 August 2021 Brett and Michelle Mitchell <Lefthanders Super Fund A/C> 8,140,560 Fully Paid Ordinary Shares 3,750,000 Performance Rights 277,777 Listed Options exercisable at $0.045 each expiring 31 August 2021 Chieftain Securities Pty Ltd 5,000,000 Unlisted Options exercisable at $0.15 expiring 30 June 2021 1,500,000 Unlisted Options exercisable at $0.05 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at $0.06 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at $0.07 expiring 31 August 2023 ------------------------------------------------------- Class Performance Rights ------------------------------------------------------- Number acquired Nil ------------------------------------------------------- Number disposed 2,500,000 -------------------------------------------------------
Value/Consideration Nil - Cancellation of performance rights Note: If consideration is non-cash, provide details and estimated valuation ------------------------------------------------------- No. of securities held Brett and Michelle Mitchell <Mitchell after change Spring Family A/C> 22,264,444 Fully Paid Ordinary Shares 2,500,000 Performance Rights 277,777 Listed Options exercisable at $0.045 each expiring 31 August 2021 Brett and Michelle Mitchell <Lefthanders Super Fund A/C> 8,140,560 Fully Paid Ordinary Shares 2,500,000 Performance Rights 277,777 Listed Options exercisable at $0.045 each expiring 31 August 2021 Chieftain Securities Pty Ltd 5,000,000 Unlisted Options exercisable at $0.15 expiring 30 June 2021 1,500,000 Unlisted Options exercisable at $0.05 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at $0.06 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at $0.07 expiring 31 August 2023 ------------------------------------------------------- Nature of change Cancellation of performance shares due Example: on-market to performance conditions lapsing. trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back -------------------------------------------------------
Part 2 - Change of director's interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract N/A Nature of interest ---- Name of registered holder (if issued securities) ---- Date of change ---- No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed ---- Interest acquired ---- Interest disposed ---- Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation ---- Interest after change ----
Part 3 - + Closed period
Were the interests in the securities No or contracts detailed above traded during a + closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? --- If prior written clearance was provided, on what date was this provided? ---
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity MGC Pharmaceuticals Limited ABN 30 116 800 269
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director Roby Reuven Zomer Date of last notice 12 August 2020 -------------------------------
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest Indirect Nature of indirect interest Chitta Lu Limited (Director (including registered holder) and sole shareholder) Note: Provide details of the circumstances giving rise to the relevant interest. -------------------------------------------------- Date of change 5 March 2021 -------------------------------------------------- No. of securities held prior Chitta Lu Limited to change 3,000,001 Fully Paid Ordinary Shares 7,500,000 Performance Rights HSBC Custody Nominees (Australia) Limited 30,000,000 Fully Paid Ordinary Shares -------------------------------------------------- Class Performance Rights -------------------------------------------------- Number acquired Nil -------------------------------------------------- Number disposed 2,500,000 Performance Rights -------------------------------------------------- Value/Consideration Non-cash - forfeited due to Note: If consideration is non-cash, not meeting performance conditions. provide details and estimated valuation -------------------------------------------------- No. of securities held after Chitta Lu Limited change 3,000,001 Fully Paid Ordinary Shares 5,000,000 Performance Rights HSBC Custody Nominees (Australia) Limited 30,000,000 Fully Paid Ordinary Shares -------------------------------------------------- Nature of change Cancellation of performance Example: on-market trade, off-market rights due to performance trade, exercise of options, conditions lapsing issue of securities under dividend reinvestment plan, participation in buy-back --------------------------------------------------
Part 2 - Change of director's interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract N/A Nature of interest ---- Name of registered holder (if issued securities) ---- Date of change ---- No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed ---- Interest acquired ---- Interest disposed ---- Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation ---- Interest after change ----
Part 3 - + Closed period
Were the interests in the securities N/A or contracts detailed above traded during a + closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? ---- If prior written clearance was provided, on what date was this provided? ----
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHGLGDXIXGDGBC
(END) Dow Jones Newswires
March 09, 2021 02:00 ET (07:00 GMT)
1 Year Mgc Pharmaceuticals Chart |
1 Month Mgc Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions